Paul Thomas Anderson's latest picks up some big wins from NBR, including Best Film, Best Director, Best Actor for Leonardo DiCaprio, Best Supporting Actor for Benicio Del Toro, and Breakthrough ...

Paul Thomas Anderson’s One Battle After Another continued its roll through the early awards season gauntlet Wednesday, when it was selected the Best Film by the National Board of Review. The group of ...

Testing the human animal’s tolerance for plaintive fiddles, wheezy bagpipes, Peter Coyote and the whispery recitations of diary entries, “The American Revolution” is the most Ken Burns-y of Ken Burns ...

In this gentle western, Josh O’Connor plays a cowboy who’s lost his ranch and sense of self to a wildfire. By Lisa Kennedy When you purchase a ticket for an independently reviewed film through our ...

Some New York City business owners say they're being extorted by fake reviewers who leave a slew of negative Google reviews and demand money for it to stop. It's become so prevalent that CBS News New ...

The iPhone 17 does everything that’s asked of it to an exceptionally high standard. The design is smart and robust; the screen is big and bright and equipped with pro features; the camera takes great ...

The FDA said it would delay feedback on a diabetes drug developed by Lexicon previously expected by the end of the month, saying it needed more time to review data Lexicon submitted. The drug, called ...

In this genre-bending thriller, an online reseller’s tale of vengeance becomes a parable of human greed and disconnection. By Brandon Yu When you purchase a ticket for an independently reviewed film ...

Turnstile’s much-anticipated follow-up to 2021’s massive Glow On is like a mysterious gallery. It’s not so much a collection of tracks, but impressions, aural vignettes that are more about a feeling ...

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...